AVTX — Avalo Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$19.41
+$0.46 (+2.43%)
Avalo Therapeutics Inc (AVTX) is a biotechnology company listed on NASDAQ. It is led by Garry A. Neil M.D., based in 540 Gaither Road, Rockville, MD, United States, 20850, with about 23 employees. Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Latest reported AVTX revenue for 2025-09-30 was $0. Net income was -$30.6M. AVTX currently screens at market cap $51.5M and trailing P/E 0.0.
Use this AVTX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the AVTX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the AVTX SEC filings page. Lician reads the product cache first so this HTML stays unique to Avalo Therapeutics Inc even when a live quote feed is slow.
About Avalo Therapeutics Inc
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
AVTX Key Statistics
Market Cap
$51.54M
Volume
1.01M
Previous Close
$19.27
Day Range
$19.36 – $20.05
P/E Ratio
0.04
EPS
-$20.91
Revenue
$441.00K
Net Income
-$35.13M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-77.1%
Profit Margin
-7965.8%
Employees
23
AVTX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $441.00K | $1.92M | $18.05M | $5.40M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$35.13M | -$31.54M | -$41.66M | -$84.38M |
| EPS (Diluted) | -$20.91 | -$113.58 | -$1.06K | $0.00 |
Total Assets
$150.73M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$134.55M
Operating Cash Flow
-$49.06M
Free Cash Flow
$0.00
Avalo Therapeutics Inc Company Information
- President, CEO & Director
- Garry A. Neil M.D.
- Headquarters
- 540 Gaither Road, Rockville, MD, United States, 20850
- Website
- www.avalotx.com
- Phone
- 410 522 8707
- IPO / Founded
- 2015-11-13
- Sector
- Healthcare
- Industry
- Biotechnology